JPH0529207B2 - - Google Patents

Info

Publication number: JPH0529207B2
Authority: JP; Japan
Prior art keywords: ngf; compound; group; compounds; secretion
Prior art date: 1986-09-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP22613586A

Other languages

English (en)

Japanese (ja)

Other versions

JPS6383020A (ja

Inventor

Noriaki Ikeda

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mitsui Toatsu Chemicals Inc

Original Assignee

Mitsui Toatsu Chemicals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-09-26

Filing date

1986-09-26

Publication date

1993-04-28

1986-09-26 Application filed by Mitsui Toatsu Chemicals Inc filed Critical Mitsui Toatsu Chemicals Inc

1986-09-26 Priority to JP61226135A priority Critical patent/JPS6383020A/ja

1987-09-23 Priority to FI874163A priority patent/FI874163A/fi

1987-09-25 Priority to KR1019870010738A priority patent/KR900001511B1/ko

1987-09-25 Priority to DK505787A priority patent/DK505787A/da

1987-09-25 Priority to NO874032A priority patent/NO874032L/no

1987-09-25 Priority to DE8787308482T priority patent/DE3777050D1/de

1987-09-25 Priority to NZ221933A priority patent/NZ221933A/xx

1987-09-25 Priority to EP87308482A priority patent/EP0261977B1/en

1987-09-25 Priority to AU78956/87A priority patent/AU603137B2/en

1988-04-13 Publication of JPS6383020A publication Critical patent/JPS6383020A/ja

1990-02-20 Priority to US07/481,677 priority patent/US4985458A/en

1990-10-31 Priority to US07/606,817 priority patent/US5102906A/en

1991-12-03 Priority to US07/801,866 priority patent/US5214034A/en

1992-04-13 Priority to NO921475A priority patent/NO921475D0/no

1993-04-28 Publication of JPH0529207B2 publication Critical patent/JPH0529207B2/ja

Status Granted legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 description 32
102100023995 Beta-nerve growth factor Human genes 0.000 description 25
108010025020 Nerve Growth Factor Proteins 0.000 description 25
230000000694 effects Effects 0.000 description 18
210000005036 nerve Anatomy 0.000 description 15
YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 14
230000028327 secretion Effects 0.000 description 11
210000004556 brain Anatomy 0.000 description 10
210000004027 cell Anatomy 0.000 description 10
238000012360 testing method Methods 0.000 description 9
101100424823 Arabidopsis thaliana TDT gene Proteins 0.000 description 8
210000001320 hippocampus Anatomy 0.000 description 8
238000000034 method Methods 0.000 description 8
230000014537 nerve growth factor production Effects 0.000 description 7
125000004432 carbon atom Chemical group C* 0.000 description 6
230000001713 cholinergic effect Effects 0.000 description 6
125000000217 alkyl group Chemical group 0.000 description 5
150000003943 catecholamines Chemical class 0.000 description 5
210000003710 cerebral cortex Anatomy 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
238000002965 ELISA Methods 0.000 description 4
230000007850 degeneration Effects 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
230000002889 sympathetic effect Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
230000006870 function Effects 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
210000000478 neocortex Anatomy 0.000 description 3
230000001737 promoting effect Effects 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
210000002186 septum of brain Anatomy 0.000 description 3
150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 2
ZBCATMYQYDCTIZ-UHFFFAOYSA-N 4-methylcatechol Chemical compound CC1=CC=C(O)C(O)=C1 ZBCATMYQYDCTIZ-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
206010003591 Ataxia Diseases 0.000 description 2
101710129634 Beta-nerve growth factor Proteins 0.000 description 2
108010058699 Choline O-acetyltransferase Proteins 0.000 description 2
102100023460 Choline O-acetyltransferase Human genes 0.000 description 2
238000005727 Friedel-Crafts reaction Methods 0.000 description 2
101150064037 NGF gene Proteins 0.000 description 2
102000007072 Nerve Growth Factors Human genes 0.000 description 2
241000700159 Rattus Species 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
210000004227 basal ganglia Anatomy 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
238000001514 detection method Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000030214 innervation Effects 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
239000003900 neurotrophic factor Substances 0.000 description 2
210000000956 olfactory bulb Anatomy 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
210000004129 prosencephalon Anatomy 0.000 description 2
230000007832 reinnervation Effects 0.000 description 2
230000008439 repair process Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
238000010998 test method Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108091008604 NGF receptors Proteins 0.000 description 1
102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
108020002494 acetyltransferase Proteins 0.000 description 1
102000005421 acetyltransferase Human genes 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000011047 acute toxicity test Methods 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000008335 axon cargo transport Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
230000003925 brain function Effects 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
-1 carbonate ester Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000004720 cerebrum Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
201000003723 learning disability Diseases 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
230000007087 memory ability Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
238000004634 pharmacological analysis method Methods 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
108020003175 receptors Chemical class 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1

Landscapes

Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

JP61226135A 1986-09-26 1986-09-26 中枢性神経退行性疾患の進行防止および治療剤 Granted JPS6383020A (ja)

Priority Applications (13)

Application Number	Priority Date	Filing Date	Title
JP61226135A JPS6383020A (ja)	1986-09-26	1986-09-26	中枢性神経退行性疾患の進行防止および治療剤
FI874163A FI874163A (fi)	1986-09-26	1987-09-23	Katekolderivat samt preparat innehaollande desamma foer haemmande och botande av regressiva sjukdomar i det centrala nervsystemet.
NZ221933A NZ221933A (en)	1986-09-26	1987-09-25	Catechol derivatives and pharmaceutical compositions
AU78956/87A AU603137B2 (en)	1986-09-26	1987-09-25	Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system containing the same
DK505787A DK505787A (da)	1986-09-26	1987-09-25	Catecholderivater samt forebyggende og terapeutisk praeparat omfattende samme mod regressive sygdomme i centralnervesystemet
NO874032A NO874032L (no)	1986-09-26	1987-09-25	Fremgangsmaate for fremstilling av terapeutisk aktive catecholderivater.
DE8787308482T DE3777050D1 (de)	1986-09-26	1987-09-25	Catecholderivate und vorbeugende sowie heilende praeparate fuer regressive stoerungen im zentralnervensystem.
KR1019870010738A KR900001511B1 (ko)	1986-09-26	1987-09-25	카테콜 유도체 및 그것을 함유하는 중추신경계 퇴행성질환의 진행방지 및 치료제
EP87308482A EP0261977B1 (en)	1986-09-26	1987-09-25	Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system
US07/481,677 US4985458A (en)	1986-09-26	1990-02-20	Catechol diacetate derivatives for inducing the production of nerve growth factor to treat degenerative diseases in the central nervous system
US07/606,817 US5102906A (en)	1986-09-26	1990-10-31	Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system containing the same
US07/801,866 US5214034A (en)	1986-09-26	1991-12-03	Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system containing the same
NO921475A NO921475D0 (no)	1986-09-26	1992-04-13	Analogifremgangsmaate for fremstilling av terapeutisk aktive catecholderivater

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP61226135A JPS6383020A (ja)	1986-09-26	1986-09-26	中枢性神経退行性疾患の進行防止および治療剤

Publications (2)

Publication Number	Publication Date
JPS6383020A JPS6383020A (ja)	1988-04-13
JPH0529207B2 true JPH0529207B2 (no)	1993-04-28

Family

ID=16840397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP61226135A Granted JPS6383020A (ja)	1986-09-26	1986-09-26	中枢性神経退行性疾患の進行防止および治療剤

Country Status (1)

Country	Link
JP (1)	JPS6383020A (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103562379A (zh) *	2011-05-19	2014-02-05	国立大学法人德岛大学	细胞分化诱导剂以及分化诱导方法
US9730497B2 (en)	2012-04-24	2017-08-15	Grand Rainbow International Limited	Closure for article, in particular for jewelry

1986
- 1986-09-26 JP JP61226135A patent/JPS6383020A/ja active Granted

Also Published As

Publication number	Publication date
JPS6383020A (ja)	1988-04-13

Publication	Publication Date	Title
Hefti et al.	1986	Nerve growth factor and Alzheimer's disease
Vallejo et al.	1987	Occurrence and extracellular actions of inositol pentakis-and hexakisphosphate in mammalian brain
US5342942A (en)	1994-08-30	Pyrazoloquinazolone derivatives as neurotrophic agents
JP2002504370A (ja)	2002-02-12	改変された毛様体神経栄養因子、それらを作製する方法およびそれらの使用方法
US5545719A (en)	1996-08-13	Nerve growth peptides
JP7486328B2 (ja)	2024-05-17	神経突起伸長促進剤、神経細胞の樹状突起発現促進剤、及び神経栄養因子様作用物質
EP0333522B1 (en)	1994-08-17	Catechol derivatives and pharmaceutical preparations containing same
EP0261977A2 (en)	1988-03-30	Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system
JP5198538B2 (ja)	2013-05-15	硫酸化多糖または硫酸化オリゴ糖を含む薬学的組成物および医薬
Takeuchi et al.	1990	Stimulation of nerve growth factor synthesis/secretion by 1, 4-benzoquinone and its derivatives in cultured mouse astroglial cells
US5232923A (en)	1993-08-03	Catechol derivatives and pharmaceutical preparations containing same
JP2011059126A5 (no)	2011-09-29
JPH0649004A (ja)	1994-02-22	アルカノイル−ｌ−カルニチンアミド誘導体および医薬組成物
JPH0529207B2 (no)	1993-04-28
Liebl et al.	1993	Serotonin‐activated α2‐macroglobulin inhibits neurite outgrowth and survival of embryonic sensory and cerebral cortical neurons
US4782073A (en)	1988-11-01	Amides of [(5,6-dichloro-3-oxo-9-alpha-substituted-2,3,9,9-alpha-tetrahydrofluoren-7-yl-oxyl]acetic acids, and pharmaceutical compositions thereof
Söderström et al.	1995	In vitro toxicity of methyl mercury: effects on nerve growth factor (NGF)-responsive neurons and on NGF synthesis in fibroblasts
US5543498A (en)	1996-08-06	Peptides to overcome inhibition of nerve growth
JPH01238524A (ja)	1989-09-22	カテコールアミン誘導体を含有してなる中枢性神経退行性疾患の進行防止および治療剤
RU2160098C2 (ru)	2000-12-10	Применение бензонафталиновых производных для получения лекарственных средств, предназначенных для лечения заболеваний нервной системы
EP0418065B1 (en)	1994-04-20	Dihydrocaffeic acid derivatives, use thereof for medical treatments and pharmaceutical preparations containing same
KR20180031532A (ko)	2018-03-28	말초신경계 질환의 치료 또는 예방용 약학 조성물
KR20220057553A (ko)	2022-05-09	인간 재조합 저시알릴화된 에리트로포이에틴, 그것의 정제 방법 및 치료 용도
CN106608824B (zh)	2019-12-20	芳酸酯类化合物及其制备方法和用途
US5290793A (en)	1994-03-01	Dihydrocaffeic acid derivatives and pharmaceutical preparation containing same